1. France Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Adocia SA

Adocia SA

2.34
EUR
-0.02
(-0.68%)
95.02MMarket Cap
Mar 03Next Earn
Adocia SA
LSE:0QAI
(London Stock Exchange)

Recent

price

2.34

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
0.03
0.35
0.67
0.9
0.11
5.52
3.28
2.84
6.85
0.31
0.12
0.2
1.43
0.15
0.63
0.08
- -
Revenue per Share
-1.17
-1.45
-1
-0.69
-3.33
1.88
-1.15
-1.25
1.1
-2.68
-3.34
-3.22
-0.86
-1.5
-0.63
-0.93
- -
Basic EPS, GAAP
-1.26
-1.44
0.03
-1.81
4.85
-1.12
-3.1
-3.53
0.8
-1.68
-3.16
-2.78
-1.89
-0.36
-1.07
-0.38
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1.73
0.7
3.72
3.1
0.4
6.88
6.23
5.34
6.62
4.04
0.91
-1.91
-1.49
-0.49
-0.2
0.08
-0.2
Book Value per Share
1.72
0.7
3.71
3.1
0.4
6.88
6.23
5.33
6.61
4.03
0.9
-1.91
-1.49
-0.49
-0.2
0.08
-0.2
Tangible Book Value per Share
4
4
6
6
6
7
7
7
7
7
7
7
8
14
15
18
15
Basic Weighted Avg Shares
- -
2
4
6
1
37
22
19
47
2
1
1
11
2
9
1
- -
Sales/Revenue/Turnover
-4,178.38
-391.68
-151.9
-76.95
-2,437.5
27.35
-35.58
-42.01
20.49
-1,027.53
-2,514.74
-1,341.07
-14.82
-662.51
-79.41
-1,068.68
- -
Operating Margin (%)
- -
- -
- -
- -
- -
1
1
1
1
1
1
1
1
- -
- -
1
- -
Depreciation Expense
-5
-6
-6
-4
-21
13
-8
-9
8
-19
-23
-23
-7
-21
-9
-17
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
35.24
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-4,262.16
-416.12
-150.03
-76.81
-2,942.47
33.98
-35.09
-43.92
16.07
-868.08
-2,773.37
-1,575.76
-60.29
-984.28
-100
-1,124.81
- -
Profit Margin (%)
12
6
24
20
31
66
42
36
46
41
26
-2
1
- -
2
4
2
Working Capital
2
2
2
2
1
1
6
6
5
19
25
18
18
11
9
6
9
LT Debt
11
4
23
19
3
47
43
37
46
28
6
-14
-13
-7
-3
1
-3
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
12.82
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
15.84
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-85.96
-43.83
-20.37
-191.5
50.66
-17.57
-21.48
18.41
-50.35
-135.71
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
2
3
3
LT Borrowings
5
3
2
LT Finance Leases
7
7
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
15
16
Market Capitalization
163
124
95

Working Capital

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
20
19
22
Cash, Cash Equivalents & STI
13
10
8
Accounts Receivable, Net
- -
- -
9
Inventories
- -
- -
- -
Total Current Liabilities
20
21
21
Payables & Accruals
- -
- -
- -
ST Debt
2
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-68.93%
-114.9%
-148.27%
Free Cash Flow
-9.5%
10.6%
-57.09%
Net Income, GAAP
-50.59%
31.32%
78%
Sales/Revenue/Turnover
86.72%
186.51%
-84.18%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2
2024
- -
- -
9
2025
- -
- -
1

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-1.5
2024
- -
- -
-0.63
2025
- -
- -
-0.93

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Adocia SA (ADOC.PA) is a clinical-stage biotechnology company that develops innovative formulations of approved therapeutic proteins and peptides, as well as novel cell therapy approaches, primarily for the treatment of diabetes and obesity; its proprietary platforms include BioChaperone for new-generation insulins and hormone combinations, AdoShell for immunoprotective islet cell transplantation, AdOral for oral peptide delivery, and AdoGel for long-acting drug delivery. Key products in its diversified pipeline encompass BioChaperone Lispro, an ultra-rapid prandial insulin formulation licensed to Tonghua Dongbao for China and select Asian markets and ready for Phase 3 trials in the US and Europe upon partnership; BioChaperone Combo, a fixed-ratio co-formulation of insulin glargine and lispro for type 2 diabetes; M1Pram and BioChaperone LisPram, pramlintide-insulin combinations with Sanofi for glycemic control and weight management in obese diabetic patients; AdoShell Islets, a retrievable hydrogel implant for type 1 diabetes cell therapy; AdOral Sema, an oral semaglutide; and AdoGel Sema, a steady-release injectable semaglutide hydrogel, with additional assets like BioChaperone GLP-1 Amylin in development. Founded in 2005 by the Soula family and headquartered in Lyon, France, the company targets patients with type 1 and type 2 diabetes and obesity globally through partnerships, with operations centered in Europe and licensing in Asia. Recent developments include a €9.7 million private placement in February 2025 led by Armistice Capital and existing shareholders, extending cash runway to Q2 2026; a US$10 million milestone from Tonghua Dongbao in 2025 following positive Phase 3 topline results for ultra-rapid BioChaperone Lispro (THDB0206) in type 1 diabetes; €10 million upfront from Sanofi for exclusive negotiation rights on M1Pram, with ongoing partnership discussions; a new patent filing in November 2025 for the AdoXLong long-acting peptides platform alongside BioChaperone updates; and oral presentations on AdoShell and BioChaperone at EASD, ESB, and PODD 2025 meetings.